Clinical trialNACompleted
Surgery Impact on Circulating Tumor DNA in Pancreatic Cancer
Influence of Pancreatic Adenocarcinoma Excision Surgery on Peripheral and Portal Circulating Tumor DNA: Prospective Exploratory Pilot Study.
- Outcome
- Finished, no results posted
- Phase
- NA
- Status
- Completed
- Study type
- Interventional
- Start
- 26 February 2018
- Expected end
- 20 June 2022
- Enrollment
- 35 participants
- Sites
- 1
- Primary outcomes
- Kinetic of circulating tumor DNA evaluation in resected pancreatic cancer.
- Sponsor
- Other
- Results posted
- No
- Last update
- 28 November 2025
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
Pancreatic cancer represents the fourth cause of death by cancer in western countries. The only curative treatment is surgery but this one is possible only in 10 to 15 % of cases. To date, there are few biomarkers in circulating blood as prognostic or diagnostic markers in pancreatic cancer. The purpose of this study is to determine if the pancreatic tumor mobilization during its resection impacts the quantity of circulating tumor DNA in peripheral and portal blood.
Detailed description public domain (ClinicalTrials.gov)
The investigators will analyze if the tumor mobilization increases circulating DNA rate in peripheral and portal blood. Moreover, circulating tumor DNA will be measured during 12 months after surgery in peripheral blood. They will use a gene mutation detection technique called Next Generation Sequencing (NGS) which is more specific than a simple Polymerase Chain Reaction (PCR).
Papers 1
- Registry-listed results paperPrognostic impact of circulating tumor DNA detection in portal and peripheral blood in resected pancreatic ductal adeno… DOI 10.1038/s41598-024-76903-y↗
The registry lists these as results papers; in a hand check of 27 such links about 78% reported the trial’s results, so read the paper before treating it as the outcome.